Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) will announce its earnings results before the market opens on Monday, November 14th. Investors interested in listening to the company’s conference call can do so using this link.
Acurx Pharmaceuticals Price Performance
NASDAQ ACXP opened at $2.91 on Friday. The firm has a market cap of $33.63 million, a PE ratio of -2.40 and a beta of -0.84. Acurx Pharmaceuticals has a one year low of $2.33 and a one year high of $5.50. The stock’s 50 day simple moving average is $3.29 and its 200 day simple moving average is $3.43.
Analyst Ratings Changes
Institutional Inflows and Outflows
An institutional investor recently raised its position in Acurx Pharmaceuticals stock. BlackRock Inc. raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Rating) by 149.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 16,699 shares of the company’s stock after buying an additional 10,014 shares during the period. BlackRock Inc. owned about 0.16% of Acurx Pharmaceuticals worth $55,000 as of its most recent filing with the SEC. 3.03% of the stock is owned by hedge funds and other institutional investors.
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.